Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Terminated 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Gastrointestinal 2Dermatologic 2CNS 2Head & Neck 1Genitourinary 1Endocrine 1

Conditions

Low-grade Glioma 3Pancreatic Neoplasms 2Melanoma 2Glioma 2Colorectal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Astrocytoma 2Urinary Bladder Neoplasms 1Thyroid Cancer, Papillary 1Neoplasms 1Diffuse Intrinsic Pontine Glioma 1Craniopharyngioma 1Brain Neoplasms 1

Interventions

Gemcitabine 5Temozolomide 3Paclitaxel 3Oxaliplatin 3Nivolumab 3Leucovorin 3Irinotecan 3Erlotinib Hydrochloride 3Bevacizumab 3ulixertinib 2tovorafenib 2pembrolizumab 2Trastuzumab 2Specimen Handling 2Radiotherapy 2Magnetic Resonance Spectroscopy 2Fluorouracil 2Fluorodeoxyglucose F18 2Docetaxel 2Cyclophosphamide 2Cetuximab 2Carboplatin 2vocimagene amiretrorepvec 1trastuzumab deruxtecan 1trastuzumab biosimilar HLX02 1trametinib 1tipifarnib 1temsirolimus 1spartalizumab 1sargramostim 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Pancreatic Neoplasms × tovorafenib × CNS × Clear all
NCT04985604 2025-10-02

Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors

Day One Biopharmaceuticals, Inc.

Phase 2 Terminated
23 enrolled 15 charts
CNSDermatologicEndocrineGastrointestinalGenitourinaryHead & NeckThoracic

Thyroid Cancer, Papillary, Astrocytoma, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Melanoma, Pancreatic Neoplasms, Colorectal Neoplasms

NCT07121829 2025-08-14

Tovorafenib (DAY101) or in Combination With Pimasertib for Participants With Melanoma and Other Solid Tumors

Day One Biopharmaceuticals, Inc.

Phase 1 Terminated
44 enrolled
CNSDermatologicGastrointestinalThoracic

Astrocytoma, Carcinoma, Non-Small-Cell Lung, Melanoma, Pancreatic Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡